US FDA approves AbbVie’s drug for Parkinson’s disease
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 2026
FDA approves Lilly’s Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata
FDA approves Lilly's Olumiant (baricitinib) for pediatric patients 12 years of age and older with severe alopecia areata PR Newswire